Ana Moran, MD
Infectious Disease · Phoenix, AZNPI 1871600916
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,058 of the $35,248 with a category attached, or 99.5%. Bayer accounts for 99.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $22,158 and has fallen 99.9% since, to $16 in 2024. Among infectious disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 13 payments — averaging $2711.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$35K
- Janssen Products, LP$85
- AbbVie$45
- Viiv Healthcare Company$32
- Gilead$16
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$13
What the payments were for
- Consulting fees$35,05899%
- Food & beverage$1050%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 5 | $35,058 |
| Janssen Products, LP | 1 | $85 |
| AbbVie | 3 | $45 |
| Viiv Healthcare Company | 2 | $32 |
| Gilead | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$12,900
How this compares
$35,248 in reported general payments places this provider in the 95th percentile of 146 infectious disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 24 | $2,232 |
| ErtapenemErtapenem Sodium | 11 | $1,912 |
| Fluconazole | 21 | $1,430 |
| Methenamine Hippurate | 22 | $1,338 |
| CeftriaxoneCeftriaxone Sodium | 14 | $502 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Phoenix
- Thanes VanigPhoenix$258K
- Vipul GanatraPhoenix$151K
- Robert OrensteinPhoenix$26K
- Adriana GaidiciPhoenix$20K
- Dwight ClarkePhoenix$18K
- Ndidiamaka ObiesiePhoenix$12K
- Ngozi OsonduPhoenix$5K
- Mirella MircescuPhoenix$4K
- Rebekah SensenigPhoenix$3K
- Edwin YuPhoenix$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.